100  Total SME IPOs listed in 2025

4,441.26 Crs.  Total funds raised in 2025

69  SME IPOs listed with Gain in 2025

31  SME IPOs listed with loss in 2025

100  Total SME IPOs listed in 2025

4,441.26 Crs.  Total funds raised in 2025

69  SME IPOs listed with Gain in 2025

31  SME IPOs listed with loss in 2025

100  Total SME IPOs listed in 2025

4,441.26 Crs.  Total funds raised in 2025

69  SME IPOs listed with Gain in 2025

31  SME IPOs listed with loss in 2025

100  Total SME IPOs listed in 2025

4441.26 Crs.  Total funds raised in 2,025.00

69  SME IPOs listed with Gain in 2025

31  SME IPOs listed with loss in 2025

Glenmark Life Sciences Limited IPO Analysis

Glenmark Life Sciences IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ 1513.60 Cr. The company is based in Solapur and caters to Pharmaceutical sector. Bob Capital Markets , Bofa Securities India , Dam Capital Advisors (Formerly Idfc Securities ) , Goldman Sachs (India) Securities are the merchant bankers of Glenmark Life Sciences IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 16th April 2021.

Glenmark Life Sciences IPO posted revenues of ₹ 1885.98 crores and PAT of ₹ 351.58 crores in FY25 on annualised basis.

IPO Key Highlights

*At the time of IPO, on Annualised Basis
  • Revenue: ₹ 1,885.17 Cr.
            EBITDA: ₹ 591.89 Cr.
            PAT: ₹ 351.58 Cr.
  • EBITDA Margin: 31.40 %
            Pat Margin: 18.65 %
  • Net Worth: ₹ 752.75 Cr.
  • Market Capitalisation: [●]
  • P/E: 25.09 times
  • P/BV: [●]
  • EV/EBITDA: -0.20 times
Nature of IPO : MainBoard
Exchange : BSE,NSE
IPO Type : Book Building

Glenmark Life IPO Financial Performance (Restated)

Financial results of Glenmark Life Sciences IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.

Amount in ₹ crores
Financials FY21 FY20 FY19
Balance Sheet
Assets 1997.08 1725.60 1475.40
Net Worth 752.75 401.69 88.13
Total Debt [●] 0.02 0.02
Profit & Loss
Revenue
Revenue on annualised basis
1885.17 1537.31 886.42
EBITDA
EBITDA on annualised basis
591.89 483.95 248.16
PAT
PAT on annualised basis
351.58 313.10 195.59
Financials
FY21
FY20
FY19
Balance Sheet
Assets
1997.08
1725.60
1475.40

Net Worth
752.75
401.69
88.13

Total Debt
0.00
0.02
0.02

Profit & Loss
Revenue
Revenue on annualised basis
1885.17
1,885.17
1537.31
886.42

EBITDA
EBITDA on annualised basis
591.89
591.89
483.95
248.16

PAT
PAT on annualised basis
351.58
351.58
313.10
195.59

Notes:
1) Total debt incluides long-term borrowings and short-term borrowings.
2) Revenue means the Revenue from Operations as appearing in the Restated Financial Statements.

Glenmark Life IPO Key performance Indicators (KPI)

Glenmark Life Sciences IPO PAT Margin is 18.65 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Glenmark Life Sciences IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.

Particulars FY21 FY20 FY19
EBITDA Margin (%) 31.40 31.48 28.00
PAT Margin (%) 18.65 20.37 22.07
EPS (₹) 32.61 29.04 24.64
ROE (%) 46.71 77.95 221.93
ROCE (%) [●] [●] [●]
ROA (%) 17.60 18.14 13.26
Debt to Equity [●] 0.00 0.00
Particulars
FY21
FY20
FY19

EBITDA Margin (%)
31.40
31.48
28.00

PAT Margin (%)
18.65
20.37
22.07

EPS (₹)
32.61
29.04
24.64

ROE (%)
46.71
77.95
221.93

ROCE (%)
[●]
[●]
[●]

ROA (%)
17.60
18.14
13.26

Debt to Equity (x)  
[●]
0.00
0.00

Notes:
1) The EPS represents post-bonus basic EPS.
2) Return on Equity is ratio of Profit after Tax and Total Equity.
3) Return on Assets is ratio of Profit after Tax and Total Assets.
4) Debt to Equity is ratio of Total borrowings and Total Equity.

Glenmark Life Sciences IPO Valuation Metrics

The market Capitalisation of Glenmark Life Sciences IPO is ₹ 0.00 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.

Key Metrics (at the time of IPO)


Market Capitalisation (₹ Cr.):
[●]

Enterprise Value (EV) (₹ Cr.):
[●]

EV/EBITDA (times) :
[●]

PE Multiple (times) :
25.09

P/B (times) :
[●]

NAV (₹) :
69.82

Notes:
1) The Enterprise Value is calculated as Market Cap. + Total Debt - Cash and Cash Equivalents.
2) Price to Book multiple is calculated as the ratio of Market Cap. and Net Worth post IPO proceeds.

What are the key financial metrics in Glenmark Life prospectus?

The Glenmark Life Sciences IPO prospectus highlights an Return on Equity (ROE) of 46.71 % , Return on Assets (ROA) of 17.60 %, and an EBITDA Margin of 31.40 %, showcasing financial performance.

How do profitability ratios impact the evaluation of Glenmark Life IPO?

Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Glenmark Life Sciences IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.

What is the market capitalisation for Glenmark Life IPO ?

The post-IPO market capitalisation of Glenmark Life Sciences IPO is ₹ 0.00 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.

What is the PE Multiple of Glenmark Life IPO?

The Glenmark Life Sciences IPO has a Price-to-Earnings (PE) ratio of 25.09 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.

What is the Revenue of Glenmark Life Sciences IPO?

Glenmark Life Sciences IPO reported revenue of ₹ 1885.98 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Glenmark Life Sciences IPO provide insights into sales growth, market demand, and business scalability.

What is the EBITDA of Glenmark Life Sciences IPO?

Glenmark Life Sciences recorded an EBITDA of ₹ 591.89 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.

What is the PAT of Glenmark Life Sciences IPO?

Glenmark Life Sciences Profit After Tax (PAT) is ₹ 351.58 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions

IPO Key Highlights

*At the time of IPO, on Annualised Basis
  • Revenue: ₹ 1,885.17 Cr.
            EBITDA: ₹ 591.89 Cr.
            PAT: ₹ 351.58 Cr.
  • EBITDA Margin: 31.40 %
            Pat Margin: 18.65 %
  • Net Worth: ₹ 752.75 Cr.
  • Market Capitalisation: [●]
  • P/E: 25.09 times
  • P/BV: [●]
  • EV/EBITDA: -0.20 times

Revenue

(As Annualised)

EBITDA

(As Annualised)

PAT

(As Annualised)
Thinking of
Listing Your Business through
SME IPO?
We can Help!
Contact Us Today

Recent IPO List

Indogulf Cropsciences Limited

  Agro

  New Delhi


HDB Financial Services Limited

  Banking and Finance

  Ahmedabad


Sambhv Steel Tubes Limited

  Steel

  Raipur


Globe Civil Projects Limited

  Engineering - EPC

  New Delhi


Ellenbarrie Industrial Gases Limited

  Oil and Gas

  Kolkata


Peer Companies Of This Sector

FAQs

Glenmark Life Sciences operates in Pharmaceutical and Developer And Manufacturer. The Issue is listed on BSE,NSE in Aug, 2021. Glenmark Life Sciences IPO size was 1513.60 with Issue price of 720.00 .

Merchant Banker(s) of Glenmark Life Sciences IPO: Bob Capital Markets Limited , Bofa Securities India Limited , Dam Capital Advisors Limited (Formerly Idfc Securities Limited) , Goldman Sachs (India) Securities Private Limited

Glenmark Life Sciences IPO subscription was 44.17 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.

Glenmark Life Sciences IPO listed at a listing price of 748.20 against the offer price of 720.00.

The current market price of Glenmark Life Sciences is 1033.10.

Services

IPO Advisory
IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Readiness
IPO Readiness
IPO Roadmap by improving Business Efficiencies, Financial Parameters and Corporate Structure to become IPO ready.
Fund Raising
Fund Raising
Fuelling a company's growth through Pre IPO Fund Raise, Private Equity, and Angel Investing.
SME : Business Scaling
SME Business Upscaling
Provide support to build a scalable SME business by unleashing the SME potential.
Post IPO Montoring
Post IPO Mentoring
Assisting with post IPO regulatory requirements and Performance Monitoring to achieve the milestone of Mainboard migration.

Thinking of
Listing Your Business through SME IPO?

We can help! Contact Us

Why Us?

  • Leading portal for IPOs
  • End to End Solutions
  • Known for Transparency